People
Takeda Oncology US Head of Sales, Annette Montandon, discusses how embodying a patient-first approach is key to the success of colorectal cancer drug FRUZAQLA®.
The Celularity CEO and founder tells BioSpace he believes that placenta-derived cells are the future of stem cell therapies to fight autoimmune disease, cancer, even aging.
Read the latest overview of people coming and going from executive positions at biopharma companies covered by BioSpace.
Read the latest overview of people coming and going from executive positions at biopharma companies that BioSpace covers.
See our latest overview of people coming and going from executive positions at biopharma companies covered by BioSpace.
Bayer cut its C-suite nearly in half amid a massive restructuring. Meanwhile, the U.S. government says it will pay for Wegovy for patients with heart disease.
As part of a sweeping reorganization, Bayer Pharmaceuticals on Wednesday shuffled its leadership roster, which included the creation of a new unit and role changes for its executives.
This is the latest rundown of people coming and going from executive positions at biopharma companies that BioSpace covers. This regular column highlights the hired, fired, retired, promoted or resigning, as well as those personally named in lawsuits.
Plus, last week Richard Gonzalez announced his retirement from AbbVie, PhRMA appointed Gilead’s O’Day to chair its board and Joseph Papa became president and CEO of Emergent.
This week Lori, Greg and Tyler discuss AbbVie: how longtime CEO Richard Gonzalez navigated Humira’s LOE, his victorious retirement announcement, and the future of biosimilars.
PRESS RELEASES